BioCryst Pharmaceuticals Inc
BCRX7.879USD
+0.179+2.32%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.65BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BioCryst Pharmaceuticals Inc Unternehmen
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Unternehmensinformationen
BörsenkürzelBCRX
Name des UnternehmensBioCryst Pharmaceuticals Inc
IPO-datumMar 04, 1994
CEOMr. Charles K. Gayer
Anzahl der mitarbeiter580
WertpapierartOrdinary Share
GeschäftsjahresendeMar 04
Addresse4505 Emperor Blvd Ste 200
StadtDURHAM
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl27703-8457
Telefon19198591302
Websitehttps://www.biocryst.com/
BörsenkürzelBCRX
IPO-datumMar 04, 1994
CEOMr. Charles K. Gayer
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
41.01K
+1.68%
Mr. Steven (Steve) Frank
Mr. Steven (Steve) Frank
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.77%
BlackRock Institutional Trust Company, N.A.
8.12%
Two Sigma Investments, LP
4.06%
State Street Global Advisors (US)
4.05%
Kynam Capital Management LP
4.03%
Andere
69.98%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.77%
BlackRock Institutional Trust Company, N.A.
8.12%
Two Sigma Investments, LP
4.06%
State Street Global Advisors (US)
4.05%
Kynam Capital Management LP
4.03%
Andere
69.98%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
36.30%
Investment Advisor/Hedge Fund
29.21%
Hedge Fund
22.32%
Research Firm
6.46%
Individual Investor
1.26%
Pension Fund
0.98%
Bank and Trust
0.45%
Family Office
0.06%
Sovereign Wealth Fund
0.05%
Andere
2.91%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
551
184.03M
87.67%
-16.63M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
UBS Financial Services, Inc.
2.40M
1.15%
+2.16M
+899.86%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
AAM Sawgrass US Small Cap Quality Growth ETF
0.44%
ProShares Hedge Replication ETF
0.07%
Fidelity Enhanced US All-Cap Equity ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Proshares Ultra Russell 2000
0%
Vanguard ESG U.S. Stock ETF
0%
iShares Russell 3000 ETF
0%
Pacer WealthShield ETF
0%
First Trust Multicap Growth Alphadex Fund
0%
Vanguard US Multifactor ETF
0%
Mehr Anzeigen
AAM Sawgrass US Small Cap Quality Growth ETF
Anteil0.44%
ProShares Hedge Replication ETF
Anteil0.07%
Fidelity Enhanced US All-Cap Equity ETF
Anteil0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Vanguard ESG U.S. Stock ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Pacer WealthShield ETF
Anteil0%
First Trust Multicap Growth Alphadex Fund
Anteil0%
Vanguard US Multifactor ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
